We are a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development.

Our generative AI platform helps us to rapidly and efficiently advance our fully self-generated AIDD pipeline primarily composed of novel drug candidates.
Global Partnerships
Global Presence

The company's team is distributed globally, allowing the company to establish a local presence in key geographies, with office sites or R&D talents in the U.S., Greater China, Canada, and the Middle East to support recruitment of top scientific talent, build relationships with new and potential biopharma partners, investors and other stakeholders and support the company's global business development function. The company has a global presence in the U.S., Greater China, Canada, and the Middle East.

With strong business development abilities, the company has received strong external validation of the company's platform with collaborations with leading industry partners around the globe, including 10 of the top 20 global pharmaceutical companies in terms of 2021 reported sales, and established collaboration with top institutions, universities, and industry leaders on the company's core AI projects.

The company has enjoyed long-term support from globally leading financial and strategic investors in technology, healthcare and AI industries, including Warburg Pincus, Qiming Venture Partners, Wuxi AppTec, B Capital Group, Prosperity 7, OrbiMed, Deerfield, Pavilion Capital, PIDC, CPE fund, Mirae Asset Capital, Lilly Asia Ventures, Eight Roads, Lake Bleu Capital, Baidu Ventures and Sinovation Ventures.
Be the first to know our news!
Once a month you will learn about our latest features and hottest news.
And no spam of course.